Intercept Pharma (ICPT) Misses Q4 Earnings

Intercept Pharmaceuticals, Inc. (ICPT) reported fourth quarter EPS of ($1.63) before the opening bell Monday, compared to the consensus estimate of ($1.62). Revenues decreased 11.1% from last year to $0.04 million. Analysts expected revenues of $0.42 million.

For the full-year 2014, net loss attributable to common stockholders was $283.2 million, or $13.63 per share, compared to a net loss of $67.8 million, or $3.76 per share, for the full year 2013. For year 2015, Intercept projects adjusted operating expenses in the range of $180 to $200 million, excluding stock-based compensation and other non-cash items.

On valuation measures, Intercept Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 552,630 shares, print a return on assets and return on equity of (25.83%) and (148.15%), respectively. The median Wall Street price target on the name is $440.00. Currently ticker boasts 10 ‘Buy’ endorsements, compared to 2 ’Holds’ and 1 ‘Sell’.

Profitability-wise, ICPT has a t-12 operating margin of (5,403%). The $4.73 billion market cap company reported $239.7 million in cash vs. $0 in debt in its most recent quarter.

ICPT currently prints a one year loss of about 48% and a year-to-date return of around 42%.

The chart below shows where the equity has traded over the last 52 weeks.

Intercept Pharmaceuticals Inc. is a development stage biopharmaceutical firm with a focus on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases. The company was founded in 2002 and is headquartered in New York.

Be the first to comment

Leave a Reply

Your email address will not be published.